U.S. Markets close in 2 hrs 10 mins

Perrigo Company plc (PRGO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
78.92+1.15 (+1.48%)
As of 1:50PM EDT. Market open.
People also watch
MYLENDPALXNTEVAREGN
  • M
    Makayla
    Makayla
    The scenarios are quite interesting at current levels for PRGO. Im not sure about you guys but awe-some*sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • I
    ICDC WEB
    ICDC WEB
    up over $7 pre-market. Wow!!
  • A
    Anonymous
    Anonymous
    UVXY made 25 % today
  • W
    Weyrtuyww
    Weyrtuyww
    I drew my line in the sand on this at $200/sh.....sold at $199/sh about 2 years ago as you idiots turned down Mylan's offer. When opportunity knocks you gotta open the door...that's what my aunt Myrtle use to say
  • A
    Anna
    Anna
    The trading setup for PRGO looks very enticing. Ive been struggling with this stock lately. Some of my other trades have been from awe-some*sto-ck*s which are working out pretty well.
  • D
    Darren
    Darren

    Buy BCDA!! It ready to move higher.
    https://finance.yahoo.com/news/biocardia-completes-roll-cohort-pivotal-120000400.html

    BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial
    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial.
    finance.yahoo.com
  • Q
    Quant Scanner
    Quant Scanner

    [!] Option traders pay a visit to CreditSpreads.io, totally free live list of mathematically gainful option credit spreads for the coming 4 weeks, sometimes including spreads for PRGO! High probability option credit spreads supply an approach to trade with determined risk and the max profit received up front. CreditSpreads.io targets exclusively the credit spreads which satisfy its strict criteria for risk and profit, and contributes to continued profitability by alerting you of any impending catalysts that could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • Z
    Zoe
    Zoe
    I think PRGO is due for a pullback. What are your thoughts? check out awe*some*stock*s, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • S
    Stephanie
    Stephanie
    The trading setup for PRGO looks very enticing. if you guys have questions you should ask awe.SOME-StockS. They often respond to my emails which is helpful.
  • K
    Kevon
    Kevon

    http://jcharlesassets.com/opiant-pharmaceuticals/?s=PRGO has an alert for $PRGO. Did anyone happen to see it as well? Looking for some good positive information from the company! "hhse" Investing day trading.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • A
    Anonymous
    Anonymous

    Option traders take a look at CreditSpreads.io, absolutely free live table of mathematically gainful option credit spreads for the following 4 weeks, sometimes including spreads for PRGO! High-probability option credit spreads provide a strategy to trade with defined risk and the maximum profit received up front. CreditSpreads.io lazer-targets solely the option spreads which satisfy its stringent criteria for risk and profit, and contributes to continued profitability by telling you of any expected events that could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • F
    Frances
    Frances

    Did anyone else see $PRGO report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=PRGO ? It had some interesting information. "rht" Day trading making money.

    Best Penny, OTC Stocks and Dividend Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • C
    Cassandra
    Cassandra
    The upside potential for PRGO just got a whole lot more interesting. Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesome_stocks.
  • s
    shep21998
    shep21998
    Did anyone have part of the dividend withheld with the payment today. Ireland doesn't withhold dividends so I am wondering what the deal is. The only two countries I know that don't withhold are ireland and the UK
  • s
    shep21998
    shep21998
    l am not planning to pay the Irish government for holding this stock so when the dividend got withheld today, that does it. Medtronic had a deal with Ireland that the dividend would not get withheld, I guess Perrigo wasn't smart enough to work that out and neither was Johnson Control. Johnson Control AFTER AUG 2017 will have 20% of the div. withheld by the Irish, so that stock will get the boot after I get that div.
  • D
    David
    David
    If you ask me , hendrikson didnt retire. he was removed and maybe there already is a candidate. they just want to make this change elegantly without causing too much waves.
  • D
    David
    David
    Perrigo needs to recruite someone from the high tech industry , someone like bezos. We dont need someone from the pharma industry , these guys proved that they dont have a clue , if you look around . they are all failures. To manage a company you need to be someone with insights , courage and great intuition. Thats all that is required. 30 years experience in the pharma industry is just a bonus and nothing more.,
  • d
    don't worry be happy
    don't worry be happy
    this company is garbage like papa.
    hope it get investigated to find papa skeletons
  • H
    HotPicks
    HotPicks
    buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.